Sudarshan Pharma Industries Limited has announced the successful obtainment of two critical certifications for its API manufacturing facility, marking a significant milestone in the company's quality assurance journey. The certifications underscore the company's commitment to maintaining global quality benchmarks and robust manufacturing practices in the pharmaceutical sector.

Certification Details

The company has secured two important certifications for its manufacturing facility located at Plot No. D 22, TGIIC-IALA, IDA-Medchal, Medchal-Malkajgiri District, Hyderabad, Telangana - 501401:

Validity and Timeline

Both certifications carry significant validity periods, providing the company with long-term compliance assurance:

Strategic Significance

These certifications represent a crucial development for Sudarshan Pharma Industries Limited's manufacturing capabilities. The GMP certification ensures that the company's manufacturing processes meet international standards for pharmaceutical production, while the ISO 9001:2015 certification validates the company's quality management systems.

The certifications cover the manufacturing of API intermediates and Active Pharmaceutical Ingredients, which are critical components in pharmaceutical production. This achievement positions the company as a reliable and compliant manufacturer in the competitive API and pharmaceutical intermediates segment.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparent communication with stakeholders. The certifications are subject to satisfactory surveillance audits to maintain their validity throughout the certification period.

These quality certifications are expected to enhance the company's credibility with existing and potential clients, particularly in international markets where GMP and ISO certifications are often mandatory requirements for pharmaceutical suppliers.

Sudarshan Pharma Industries Limited has submitted an updated investor presentation to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation provides comprehensive insights into the company's business operations, strategic initiatives, and financial performance.

Company Milestones and Strategic Development

The presentation outlines the company's evolution from 2008 to 2026, demonstrating consistent growth and expansion. Key developments include the establishment of manufacturing capabilities, market expansion across multiple states, and strategic acquisitions.

Recent Strategic Initiatives

The company has undertaken significant strategic initiatives in recent years, including major acquisitions and expansion plans.

Business Operations and Vertical Integration

The company focuses on vertical integration across the pharmaceutical value chain, spanning from R&D to branded generics. This strategy encompasses chemical raw materials for pharmaceuticals, intermediates for API, API manufacturing and import, finished formulation development, and branded generics production.

The business operates through multiple subsidiaries including wholly-owned entities Ratna Lifescience Private Limited and Life Science Chemical Private Limited, along with majority stakes in other pharmaceutical companies. The Hyderabad manufacturing unit specializes in bulk drug and intermediate manufacturing with approximately 50 potential API key starting materials.

Market Position and Client Base

The presentation highlights the company's extensive client portfolio, including major pharmaceutical companies such as Cipla, Biocon, Sun Pharma, Lupin, Zydus, and Takeda. The company has established export operations across multiple countries including the USA, Canada, UK, Netherlands, UAE, Australia, and various African markets.

Financial Performance Overview

The company has demonstrated consistent financial growth across key metrics. Revenue from operations increased from Rs. 463.54 Crores in FY24 to Rs. 505.05 Crores in FY25. EBITDA showed substantial improvement from Rs. 22.80 Crores in FY24 to Rs. 39.90 Crores in FY25, while PAT grew from Rs. 11.46 Crores to Rs. 15.88 Crores during the same period.

Leadership and Management

The presentation features the company's leadership team, including Chairman & Managing Director Mr. Hemal V. Mehta with 26 years of pharmaceutical industry experience, and Joint Managing Director & CFO Mr. Sachin V. Mehta. The board includes independent directors with extensive expertise in biotechnology, legal affairs, and pharmaceutical operations.